- Audience: 12.1K
- Video Views: 91.5K
- # videos: 23
-
Category:
Health
Knowledge
Lifestyle
-
Date Created: 2016-04-21
-
Date Updated: 2024-07-05
Audience activity: 7
Views per video: 3.98K
Keywords:
tresiba
fiasp
ozempic
insulin degludec
insulin aspart
semaglutide
novo nordisk
novo nordisk hcp
novo nordisk diabetes
novo nordisk insulin pen
tresiba insulin
fiasp insulin
tresiba flextouch
fiasp flextouch
ozempic injection
glp 1 mechanism of action
glp 1 receptor agonist
glp 1 ra
insulin moa
insulin dosing
tresiba dosing
Specially created for HCPs practicing in the United States, this channel focuses on a variety of products from Novo Nordisk. Keep watching to find out more about Novo Nordisk treatments, including Fiasp® (insulin aspart injection) 100 U/mL; Tresiba® (insulin degludec) injection 100 Units/mL, 200 Units/mL; Ozempic® (semaglutide) injection 0.5 mg 1 mg, or 2 mg; and RYBELSUS® (semaglutide) tablets 7 mg or 14 mg. Novo Nordisk has been driving innovation and change in health care for almost 100 years.
Subscribe to stay up to date on videos for HCPs about Novo Nordisk treatments.
Fiasp®, Ozempic®, RYBELSUS®, and Tresiba® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved. US22OZM00829 August 2022